Intragastric Balloons Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Intragastric Balloons Market is projected to expand from USD 86.27 Million in 2025 to USD 178.85 Million by 2031, registering a CAGR of 12.92%. These temporary, minimally invasive devices function by occupying gastric space to induce early satiety, effectively addressing the critical treatment gap between conservative lifestyle adjustments and invasive bariatric surgeries. This market growth is fundamentally driven by the escalating global burden of obesity, which demands scalable therapeutic solutions. For instance, the World Obesity Federation projected in 2024 that the number of adults living with obesity worldwide would rise to 1.53 billion by 2035, creating sustained demand for non-surgical weight management options with a more favorable risk profile than permanent surgical procedures.

However, despite the clear demand, market expansion faces significant hurdles regarding device safety and potential adverse events. Reports of complications, such as spontaneous balloon hyperinflation, acute pancreatitis, and gastric perforation, have triggered increased regulatory scrutiny and safety alerts that diminish patient confidence and adoption rates. Additionally, financial barriers further restrict market access, as high procedural costs are often compounded by inconsistent or limited reimbursement coverage from insurance payers, preventing a substantial portion of the eligible patient population from accessing these treatments.

Market Drivers

The primary catalyst propelling the intragastric balloons market is the rising global prevalence of obesity and overweight populations, which necessitates effective interventions to bridge the divide between lifestyle modifications and invasive surgeries. As body mass index levels increase globally, healthcare systems are turning to scalable, device-based therapies to alleviate the burden of obesity-related comorbidities. This demographic pressure is highlighted by recent surveillance data; a December 2025 report by KGOU citing Centers for Disease Control and Prevention data revealed that in 2024, at least one in four adults across all U.S. states and territories lived with obesity, underscoring the severity of this public health crisis and the resulting demand for non-surgical therapeutic alternatives.

Market growth is further accelerated by technological innovations in swallowable and adjustable balloon designs, which address patient apprehensions regarding the risks and invasiveness of traditional endoscopic placement. Next-generation, pill-based delivery systems enable procedure-less deployment, thereby enhancing patient compliance and broadening the market to those seeking reversible, lower-risk options. The commercial success of these advancements is evident; Allurion Technologies reported in June 2025 that its B2B2C sales model achieved over 40% growth in Europe, indicating strong consumer uptake. Furthermore, the segment's financial viability was reinforced when Allurion announced a full-year 2024 revenue of $32.1 million in March 2025, demonstrating the increasing utilization of these technologies.

Market Challenges

A major impediment to the growth of the global intragastric balloons market is the persistent concern surrounding device safety and adverse events. While these devices are designed to be minimally invasive, incidents of serious complications - including spontaneous hyperinflation, acute pancreatitis, and gastric perforation - have led to intensified regulatory scrutiny, safety alerts, and mandatory product recalls. These issues directly undermine patient confidence and deter healthcare providers from recommending the therapy. Consequently, for a significant segment of eligible patients, the fear of potential clinical risks often outweighs the perceived benefits, resulting in hesitancy and limited market penetration.

The tangible impact of these safety challenges is evident in the sharp contraction of procedural volumes. According to the American Society for Metabolic and Bariatric Surgery, the estimated number of intragastric balloon procedures in the United States fell to 1,461 in 2023, a significant decline from the 4,358 procedures recorded the prior year. This substantial decrease illustrates how safety-related apprehensions and the resulting caution within clinical practice are effectively stifling market growth, preventing the technology from reaching the scale needed to meet the escalating demand for non-surgical weight loss interventions.

Market Trends

The intragastric balloons market is being reshaped by the integration of AI-driven digital health ecosystems, shifting the industry focus toward comprehensive care models. Manufacturers are increasingly pairing devices with algorithmic coaching platforms that track real-time physiological metrics to improve patient safety and adherence. This digital layer facilitates personalized interventions that support essential clinical outcomes, such as muscle preservation during weight loss. The value of this approach was highlighted by Allurion Technologies in May 2025; in a press release regarding data presented at the European Congress on Obesity, the company reported that patients using its AI-powered Virtual Care Suite achieved an average lean body mass increase of 6.1% over four months, validating the efficacy of digital adjuncts.

Concurrently, a new high-efficacy treatment paradigm is emerging through combination therapies that pair intragastric balloons with GLP-1 receptor agonists. By utilizing the balloon's mechanical satiety, clinicians can prescribe lower pharmaceutical dosages to minimize side effects while enhancing overall weight loss. This synergistic approach maximizes fat reduction and overcomes the limitations of standalone pharmacotherapy, such as weight loss plateaus. The potency of this strategy was underscored in November 2025, when Allurion Technologies released data showing that patients on a regimen of its Smart Capsule and low-dose tirzepatide achieved an average total body weight loss of 23% after 12 months, a result significantly surpassing historical outcomes for device-only interventions.

Key Players Profiled in the Intragastric Balloons Market

• Apollo Endosurgery, Inc.
• Allurion Technologies, Inc.
• Obalon Therapeutics, Inc.
• Medtronic PLC
• GI Dynamics, Inc.
• Spatz Medical, Inc.
• Lexel Medical, Inc.
• Bariatric Solutions, Inc.
• Endogastric Solutions, Inc.
• Reshape Lifesciences, Inc.

Report Scope

In this report, the Global Intragastric Balloons Market has been segmented into the following categories:

Intragastric Balloons Market, by Administration:

• Pill Form v/s Endoscopy

Intragastric Balloons Market, by Balloon Type:

• Single
• Dual
• Triple

Intragastric Balloons Market, by Filling Type:

• Saline Filled v/s Gas Filled

Intragastric Balloons Market, by Application:

• Obesity
• Diabetes
• Diet Control
• Others

Intragastric Balloons Market, by End User:

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Intragastric Balloons Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Intragastric Balloons Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.